Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research

The article highlights eMTBR-Tau as a non-invasive, blood-based test to measure tau tangle burden, a key pathology linked to Alzheimer’s disease progression and cognitive decline. No performance, study results, regulatory status, or adoption milestones are provided, so near-term financial impact appears limited based on the information available.

Analysis

The article highlights eMTBR-Tau as a non-invasive, blood-based test to measure tau tangle burden, a key pathology linked to Alzheimer’s disease progression and cognitive decline. No performance, study results, regulatory status, or adoption milestones are provided, so near-term financial impact appears limited based on the information available.